FDA Issues Form 483 to Eli Lilly & Company

24 Mar 2025 //

FDA

Enforcement Report - Week of April 24, 2024

24 Apr 2024 //

FDA

FDA Issues Form 483 to Eli Lilly and Company

02 May 2023 //

FDA

Enforcement Report - Week of March 29, 2023

29 Mar 2023 //

FDA

Enforcement Report - Week of October 20, 2021

20 Oct 2021 //

FDA

Bayer Issues Voluntary Recall of Lotrimin and Tinactin Spray Products

02 Oct 2021 //

FDA

Eli Lilly & Co. Issues Voluntary Nationwide Recall of Glucagon Emergency Kit

26 Sep 2021 //

FDA

Enforcement Report - Week of September 1, 2021

01 Sep 2021 //

FDA

FDA issues form 483 to Jubilant Generics

20 Aug 2021 //

FDA

Enforcement Report - Week of August 18, 2021

18 Aug 2021 //

FDA

FDA issues form 483 to Eli Lilly

12 Aug 2021 //

FDA

J&J Slams Ex-FDA Chief in Male Breast-Growth Case

04 Feb 2015 //

BLOOMBERG BUSINESS

Eli Lilly`s Generic Duloxetine Lilly (60 mg,120 mg,90 mg) Approved in Europe for Depression,Neuropathic Pain and Generalized Anxiety Disorder

26 Jan 2015 //

ELI LILLY

Lilly and Incyte Announce Positive Top-Line Results From Phase 3 Trial of Baricitinib in Moderate to Severe Rheumatoid Arthritis

09 Dec 2014 //

PRNEWSWIRE

J&J Discount Offer Wins NICE Over to New Use for Stelara